WO2005052574A3 - Agents diagnostiques et therapeutiques destines a des maladies associees a la sous-famille k du canal potassique, element 4 (kcnk4) - Google Patents

Agents diagnostiques et therapeutiques destines a des maladies associees a la sous-famille k du canal potassique, element 4 (kcnk4) Download PDF

Info

Publication number
WO2005052574A3
WO2005052574A3 PCT/EP2004/012894 EP2004012894W WO2005052574A3 WO 2005052574 A3 WO2005052574 A3 WO 2005052574A3 EP 2004012894 W EP2004012894 W EP 2004012894W WO 2005052574 A3 WO2005052574 A3 WO 2005052574A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
kcnk4
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2004/012894
Other languages
English (en)
Other versions
WO2005052574A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005052574A2 publication Critical patent/WO2005052574A2/fr
Publication of WO2005052574A3 publication Critical patent/WO2005052574A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une KCNK4 humaine associée aux troubles cardio-vasculaires, cancers, troubles gastroentérologiques, troubles hématologiques, troubles neurologiques et troubles urologiques. L'invention concerne également des essais destinés à identifier des composés utiles dans le traitement ou la prévention des troubles cardio-vasculaires, cancers, troubles gastroentérologiques, troubles hématologiques, troubles neurologiques et troubles urologiques. Elle concerne enfin des composés se liant à l'activité de la KCNK4 et/ou activant ou inhibant celle-ci, ainsi que des compositions pharmaceutiques renfermant de tels composés.
PCT/EP2004/012894 2003-11-27 2004-11-13 Agents diagnostiques et therapeutiques destines a des maladies associees a la sous-famille k du canal potassique, element 4 (kcnk4) WO2005052574A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027371 2003-11-27
EP03027371.8 2003-11-27

Publications (2)

Publication Number Publication Date
WO2005052574A2 WO2005052574A2 (fr) 2005-06-09
WO2005052574A3 true WO2005052574A3 (fr) 2005-11-10

Family

ID=34626382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012894 WO2005052574A2 (fr) 2003-11-27 2004-11-13 Agents diagnostiques et therapeutiques destines a des maladies associees a la sous-famille k du canal potassique, element 4 (kcnk4)

Country Status (1)

Country Link
WO (1) WO2005052574A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024178364A1 (fr) * 2023-02-24 2024-08-29 The General Hospital Corporation Thérapie génique pour le traitement de la douleur

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUPRAT F ET AL: "The neuroprotective agent riluzole activates the two P domain K+ channels TREK-1 and TRAAK", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 57, no. 5, May 2000 (2000-05-01), pages 906 - 912, XP002256646, ISSN: 0026-895X *

Also Published As

Publication number Publication date
WO2005052574A2 (fr) 2005-06-09

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2006010498A3 (fr) Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2)
WO2005022146A3 (fr) Diagnostics et traitements de maladies associees a la kallikreine 13 (klk13)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005052574A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la sous-famille k du canal potassique, element 4 (kcnk4)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2005093423A3 (fr) Diagnostic et traitement de maladies associees au recepteur active de la proliferation des peroxysomes alpha (ppara)
WO2005026719A3 (fr) Diagnostic et traitement de maladies associees au transporteur de cations organiques slc22a3 (slc22a3)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005040791A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr)
WO2005026724A3 (fr) Substances pour diagnostic et traitement d'affections associees au transporteur de cations organiques slc22a5
WO2005054867A3 (fr) Diagnostics et therapeutique pour maladies associees au canal potassique de la sous-famille k, membre 5 (kcnk5)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005052587A3 (fr) Diagnostic et traitement de maladies associees au canal potassium, sous-famille k, element 7 (kcnk7)
WO2005054866A3 (fr) Agents diagnostiques et therapeutiques utilises dans le traitement des maladies associees au canal potassique de domaine a deux pores (kcnk2)
WO2004071377A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la photodiesterase 3a (pde3a)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2005054865A3 (fr) Agents diagnostiques et therapeutiques utilises dans le traitement de maladies associees au canal potassique a rectification entrante couple a une proteine (girk1)
WO2004106936A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au purinorecepteur p2y9 couple aux proteines g
WO2004073591A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la prostaglandine e2 ep2 du recepteur de la proteine g
WO2005052586A3 (fr) Elements de diagnostic et de therapie pour des maladies associees au canal potassique, sous famille k et element 3 (kcnk3)
WO2005031359A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a l'arginyl aminopeptidase (rnpep)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase